Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA414
- Development stage
- Phase 1
- Lead developer
- Chengdu Diao Jiuhong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DA414 is an orally administered small molecule drug candidate being developed as granules for the treatment of acute ischemic stroke and other vascular disorders. It is currently in Phase 1 clinical trials in China, with studies focused on evaluating its safety, tolerability, pharmacokinetics (PK), and food effects in healthy subjects. The drug has shown promising preclinical efficacy in both *in vitro* and *in vivo* models related to ischemic stroke. The precise mechanism of action for DA414 remains undefined at this stage. The developer and sponsor of the clinical program is Chengdu Diao Jiuhong Pharmaceutical Factory[1][2][3][4][5][7].
- Other names
- DA414 GranulesDA-414 GranulesDA 414 Granules
Beyond the preview
Go deeper on DA414.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA414.